labetalol has been researched along with Pre-Eclampsia in 103 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Pre-Eclampsia: A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to compare the cerebral hemodynamic effects of magnesium sulfate (MgSO4) and labetalol in pre-eclampsia patients with severe features." | 9.69 | Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler. ( Medhat, MM; Mowafy, SMS, 2023) |
| "The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension." | 9.69 | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). ( Ashworth, D; Battersby, C; Bick, D; Chappell, LC; Green, M; Hardy, P; Leighton, L; Magee, LA; Maher, A; McManus, RJ; Moakes, C; Morris, RK; Myers, J; Nelson-Piercy, C; Rivero-Arias, O; Sparkes, J; Webb, A; Wilson, H, 2023) |
| "The objectives were to compare the efficacy and safety of intravenous hydralazine and labetalol for acutely lowering severe hypertension in pregnancy." | 9.51 | Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial. ( Bako, B; Dawha, YM; Muhammad, S; Usman, H; Yahya, A; Yekeen, A, 2022) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 9.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "These nonrandomised comparisons are subject to residual confounding, but women treated with methyldopa (versus labetalol), particularly those with pre-existing hypertension, may have had better outcomes." | 9.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| "In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared." | 9.22 | Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( Shi, DD; Wang, N; Yang, FZ; Zhou, L, 2016) |
| "To assess the efficacy and safety of nicardipine in comparison to labetalol in the initial management of severe hypertension in pregnancy." | 9.10 | Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. ( Abroug, F; Boussarssar, M; Elatrous, S; Marghli, S; Nouira, S; Ouanes Besbes, L; Sakkouhi, M, 2002) |
| "Our purpose was to compare the hemodynamic effects of orally administered nifedipine and intravenously administered labetalol in preeclamptic hypertensive emergencies." | 9.09 | A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. ( Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 9.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH)." | 9.08 | Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. ( al-Fadly, A; el-Qarmalawi, AM; Hashem, M; Morsy, AH; Obeid, A, 1995) |
| "The effect of intravenous infusion of labetalol and of dihydralazine in increasing doses was compared in 12 women with severe hypertension in pregnancy." | 9.05 | Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. ( Davey, DA; Dommisse, J; Garden, A, 1982) |
| "To compare the efficacy of intravenous Labetalol and intravenous Hydralazine in reduction of blood pressure in patients with severe pre-eclampsia." | 8.31 | Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women. ( Husain, S; Hussain, R; Kausar, M, 2023) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 7.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| "The aim of the study was to investigate cord blood leptin concentrations and their relationship to birth weight and gender in term pregnancies complicated by pre-eclampsia." | 7.70 | Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia. ( Hartmann, BW; Laml, T; Preyer, O; Ruecklinger, E; Soeregi, G; Wagenbichler, P, 2000) |
| "We prospectively studied the effects of oral labetalol therapy in patients with moderate to severe pregnancy induced hypertension (PIH)." | 7.68 | Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome. ( Bjornsson, S; Calder, AA; Mahmoud, TZ, 1993) |
| "On the 3rd day after a cesarean section, because of pre-eclampsia, blood pressure was still high, oral labetalol 100 mg with an 8-hour interval was given, followed by 50 mg i." | 7.68 | Hemodynamic collapse following labetalol administration in preeclampsia. ( Beier-Holgersen, R; Olsen, KS, 1992) |
| "Labetalol was given to control blood pressures (BP) with PPE." | 6.87 | Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. ( Li, L; Li, XY; Liu, XW; Sun, CJ; Zhang, WY, 2018) |
| "Two hundred primigravid women with mild preeclampsia at 26-35 weeks' gestation were randomly allocated to treatment with hospitalization alone or combined with labetalol." | 6.66 | A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. ( Gonzalez, AR; Mabie, WC; Moretti, M; Sibai, BM, 1987) |
| " The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control." | 6.66 | A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. ( Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987) |
| "Twenty-five women with preeclampsia who were scheduled to undergo cesarean section under general anesthesia were randomly assigned to either a labetalol pretreatment group (n = 15) or a control group (n = 10) who did not receive any antihypertensive therapy before the induction of anesthesia." | 6.66 | The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. ( Chauhan, D; Mabie, WC; Ramanathan, J; Ruiz, AG; Sibai, BM, 1988) |
| " Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)." | 5.91 | Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia. ( Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023) |
| "The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension." | 5.69 | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). ( Ashworth, D; Battersby, C; Bick, D; Chappell, LC; Green, M; Hardy, P; Leighton, L; Magee, LA; Maher, A; McManus, RJ; Moakes, C; Morris, RK; Myers, J; Nelson-Piercy, C; Rivero-Arias, O; Sparkes, J; Webb, A; Wilson, H, 2023) |
| " This study aimed to compare the cerebral hemodynamic effects of magnesium sulfate (MgSO4) and labetalol in pre-eclampsia patients with severe features." | 5.69 | Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler. ( Medhat, MM; Mowafy, SMS, 2023) |
| " Among them, 51 patients in the control group were treated with magnesium sulfate combined with nifedipine, and 49 patients in the experimental group were treated with labetalol on the basis of the treatment in the control group." | 5.56 | Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. ( Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020) |
| "The objectives were to compare the efficacy and safety of intravenous hydralazine and labetalol for acutely lowering severe hypertension in pregnancy." | 5.51 | Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial. ( Bako, B; Dawha, YM; Muhammad, S; Usman, H; Yahya, A; Yekeen, A, 2022) |
| "In 14 patients with preeclampsia, 55 hypertensive emergencies were identified (BP >150/95)." | 5.46 | A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. ( Arjona-Berral, JE; Castelo-Branco, C; Duro-Gómez, J; Duro-Gómez, L; Giménez de Azcárete, M; Hernández-Angeles, C; Rodríguez-Marín, AB, 2017) |
| "Recent studies have shown a benefit to more aggressive treatment of mild chronic hypertension to a blood pressure goal of <140/90 with oral labetalol and nifedipine remaining first-line agents." | 5.41 | Cardiac medications in obstetric patients. ( Albert-Stone, E; Davis, MB; Spehar, SM, 2023) |
| "Hypotension is more common after maternal labetalol exposure, regardless of the dosage and route of administration." | 5.38 | Neonatal side effects of maternal labetalol treatment in severe preeclampsia. ( Heida, KY; Hulzebos, CV; Van Veen, TR; Zeeman, GG, 2012) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 5.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "The use of labetalol and nifedipine were not related to any significant changes in fetal Doppler, which is reassuring about the safety of these drugs when treating acute severe hypertension in pregnancy." | 5.30 | To study the changes in fetal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension. ( Gainder, S; Prakash, M; Saha, SC; Thakur, M, 2019) |
| "This was a nested cohort study of women with chronic hypertension and a singleton pregnancy recruited to the PANDA (Pregnancy And chronic hypertension: NifeDipine vs lAbetalol as antihypertensive treatment) study at one of three UK maternity units." | 5.30 | Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study. ( Chappell, LC; Cruickshank, JK; Khalil, A; Mills, C; Myers, JE; Nelson-Piercy, C; Seed, PT; Watt-Coote, I; Webster, LM, 2019) |
| "Twenty mothers with moderate to severe preeclampsia were allocated to labetalol (Trandate) or hydralazine (Apresolin) antihypertensive treatment." | 5.29 | Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment. ( Faxelius, G; Hjertberg, R; Lagercrantz, H, 1993) |
| " In the setting of hypertensive disorders of pregnancy, oral antihypertensive medications should be initiated when systolic blood pressure is greater than 160 mm Hg or when diastolic blood pressure is greater than 110 mm Hg, with the most ideal agents being labetalol or nifedipine." | 5.22 | Hypertensive Disorders of Pregnancy: Common Clinical Conundrums. ( Dotters-Katz, S; Kuller, JA; Lim, SL; Ohamadike, O; Siegel, A; Zemtsov, G, 2022) |
| "In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared." | 5.22 | Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( Shi, DD; Wang, N; Yang, FZ; Zhou, L, 2016) |
| "These nonrandomised comparisons are subject to residual confounding, but women treated with methyldopa (versus labetalol), particularly those with pre-existing hypertension, may have had better outcomes." | 5.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| "To assess the efficacy and safety of nicardipine in comparison to labetalol in the initial management of severe hypertension in pregnancy." | 5.10 | Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. ( Abroug, F; Boussarssar, M; Elatrous, S; Marghli, S; Nouira, S; Ouanes Besbes, L; Sakkouhi, M, 2002) |
| "Our purpose was to compare the hemodynamic effects of orally administered nifedipine and intravenously administered labetalol in preeclamptic hypertensive emergencies." | 5.09 | A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. ( Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 5.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH)." | 5.08 | Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. ( al-Fadly, A; el-Qarmalawi, AM; Hashem, M; Morsy, AH; Obeid, A, 1995) |
| "The effect of intravenous infusion of labetalol and of dihydralazine in increasing doses was compared in 12 women with severe hypertension in pregnancy." | 5.05 | Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. ( Davey, DA; Dommisse, J; Garden, A, 1982) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| "To compare the efficacy of intravenous Labetalol and intravenous Hydralazine in reduction of blood pressure in patients with severe pre-eclampsia." | 4.31 | Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women. ( Husain, S; Hussain, R; Kausar, M, 2023) |
| " The American College of Obstetricians and Gynecologists recommends that acute-onset, severe hypertension be treated with first line-therapy (intravenous labetalol, intravenous hydralazine or oral nifedipine) within 60 minutes to reduce risk of maternal morbidity and death." | 3.96 | Identification of factors associated with delayed treatment of obstetric hypertensive emergencies. ( Akerman, MB; Elsayad, A; Halpern, TA; Heiselman, CJ; Heo, HJ; Kantorowska, A; Muscat, JC; Sicuranza, GB; Vintzileos, AM, 2020) |
| "There may be an opportunity to reduce use of β-blockers and carboprost among patients with asthma." | 3.88 | Use of Antihypertensive Medications and Uterotonics During Delivery Hospitalizations in Women With Asthma. ( Ananth, CV; Booker, WA; Cleary, KL; DʼAlton, ME; Friedman, AM; Huang, Y; Siddiq, Z; Wright, JD, 2018) |
| "To determine whether the incidence of hypotension or adverse fetal heart tracing (FHT) category change differed following antepartum administration of intravenous (IV) labetalol versus hydralazine." | 3.83 | Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low. ( Aghajanian, P; Greene, N; Kilpatrick, SJ; Rodriguez, M; Sharma, KJ, 2016) |
| " Antenatally, her blood pressure was controlled with labetalol, and blood tests including serum creatinine were within normal limits for pregnancy." | 3.81 | Fulminant antenatal pulmonary oedema in a woman with hypertension and superimposed preeclampsia. ( Kubota-Sjogren, Y; Nelson-Piercy, C, 2015) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 3.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| "These findings demonstrate that agents commonly used for the treatment of hypertensive disease in pregnancy, excluding alpha-methyldopa, have significant direct effects on the feto-placental circulation." | 3.72 | Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance. ( Dennedy, MC; Houlihan, DD; Morrison, JJ; Ravikumar, N, 2004) |
| "Transcranial Doppler (TCD) ultrasound was used to measure the blood velocity in the middle cerebral arteries (MCA) of eight pregnant patients with hypertension, before and after the administration of a 200 mg oral dose of labetalol." | 3.71 | Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas. ( Allen, JC; Belfort, MA; Dizon-Townson, D; Tooke-Miller, C; Varner, MA, 2002) |
| "The aim of the study was to investigate cord blood leptin concentrations and their relationship to birth weight and gender in term pregnancies complicated by pre-eclampsia." | 3.70 | Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia. ( Hartmann, BW; Laml, T; Preyer, O; Ruecklinger, E; Soeregi, G; Wagenbichler, P, 2000) |
| "We prospectively studied the effects of oral labetalol therapy in patients with moderate to severe pregnancy induced hypertension (PIH)." | 3.68 | Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome. ( Bjornsson, S; Calder, AA; Mahmoud, TZ, 1993) |
| "On the 3rd day after a cesarean section, because of pre-eclampsia, blood pressure was still high, oral labetalol 100 mg with an 8-hour interval was given, followed by 50 mg i." | 3.68 | Hemodynamic collapse following labetalol administration in preeclampsia. ( Beier-Holgersen, R; Olsen, KS, 1992) |
| "Hypertension during pregnancy is associated with a higher risk of cardiovascular disease and kidney failure." | 3.01 | Evaluation and Management of Hypertensive Disorders of Pregnancy. ( Bajpai, D; Dumanski, S; Popa, C; Shah, S; Verma, P, 2023) |
| "Labetalol was given to control blood pressures (BP) with PPE." | 2.87 | Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. ( Li, L; Li, XY; Liu, XW; Sun, CJ; Zhang, WY, 2018) |
| "Normal pregnancy is a complex and dynamic process that requires significant adaptation from the maternal system." | 2.66 | Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond. ( Doherty, A; Kingdom, JC; McLaughlin, K, 2020) |
| " The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control." | 2.66 | A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. ( Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987) |
| "Twenty-five women with preeclampsia who were scheduled to undergo cesarean section under general anesthesia were randomly assigned to either a labetalol pretreatment group (n = 15) or a control group (n = 10) who did not receive any antihypertensive therapy before the induction of anesthesia." | 2.66 | The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. ( Chauhan, D; Mabie, WC; Ramanathan, J; Ruiz, AG; Sibai, BM, 1988) |
| "Two hundred primigravid women with mild preeclampsia at 26-35 weeks' gestation were randomly allocated to treatment with hospitalization alone or combined with labetalol." | 2.66 | A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. ( Gonzalez, AR; Mabie, WC; Moretti, M; Sibai, BM, 1987) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Women with chronic hypertension are at significant risk for maternal and fetal morbidity and mortality, yet it remains unclear whether antihypertensive treatment during pregnancy lowers these risks." | 2.55 | New Evidence in the Management of Chronic Hypertension in Pregnancy. ( August, P; Podymow, T, 2017) |
| "Preeclampsia is characterized by blood pressure greater than 140/90 mmHg in the second half of pregnancy." | 2.55 | Pathophysiology and Current Clinical Management of Preeclampsia. ( Amaral, LM; LaMarca, B; Owens, M; Wallace, K, 2017) |
| "Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment." | 2.43 | Pathophysiology and medical management of systemic hypertension in preeclampsia. ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006) |
| "While nitroprusside is commonly used to treat severe hypertension, it is an extremely toxic drug that should only be used in rare circumstances." | 2.41 | The diagnosis and management of hypertensive crises. ( Marik, PE; Varon, J, 2000) |
| "The etiology of preeclampsia is still unknown." | 2.41 | Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers. ( Bolte, AC; Dekker, GA; van Geijn, HP, 2001) |
| " Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)." | 1.91 | Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia. ( Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023) |
| "The HDP spectrum includes gestational hypertension (HTN), preeclampsia, eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, chronic HTN, and chronic HTN with superimposed preeclampsia." | 1.72 | Hypertensive Conditions: Hypertensive Disorders in Pregnancy. ( Daly, PL; Goodwin, ET; Kipnis, CM; Smith, DK, 2022) |
| "Hypertension in pregnancy is associated with increased cardiovascular risk." | 1.62 | Severe hypertension in pregnancy. ( Damodaram, M; Frise, C; Wiles, K, 2021) |
| " Among them, 51 patients in the control group were treated with magnesium sulfate combined with nifedipine, and 49 patients in the experimental group were treated with labetalol on the basis of the treatment in the control group." | 1.56 | Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. ( Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020) |
| "Labetalol treatment was appropriately initiated in many cases; however, protocol adherence could greatly improve." | 1.48 | Management of Hypertension on the Labor and Delivery Unit: Delivering Care in the Era of Protocols and Algorithms. ( Duong, J; Haring, A; Kuhlmann, Z; O'brien, L; Winterton, T, 2018) |
| "In 14 patients with preeclampsia, 55 hypertensive emergencies were identified (BP >150/95)." | 1.46 | A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. ( Arjona-Berral, JE; Castelo-Branco, C; Duro-Gómez, J; Duro-Gómez, L; Giménez de Azcárete, M; Hernández-Angeles, C; Rodríguez-Marín, AB, 2017) |
| "Preeclampsia is characterised by systemic endothelial cell dysfunction thought to be triggered by toxic/dangerous factors from the placenta, including placental extracellular vesicles (EVs)." | 1.46 | Treating normal early gestation placentae with preeclamptic sera produces extracellular micro and nano vesicles that activate endothelial cells. ( Chamley, LW; Chen, Q; Stone, PR; Tong, M; Wise, MR; Xiao, F; Xiao, X; Zhao, M, 2017) |
| "Hypocalcemia is a complication that must be monitored when a treatment with high doses of intravenous magnesium sulphate is introduced." | 1.40 | [Electrolyte disorders in preeclampsia. A case report]. ( Bodenmann Gobin, P; Ducry, J; Gobin, N; Portmann, L; Vial, Y; Vogt, B, 2014) |
| "Hypotension is more common after maternal labetalol exposure, regardless of the dosage and route of administration." | 1.38 | Neonatal side effects of maternal labetalol treatment in severe preeclampsia. ( Heida, KY; Hulzebos, CV; Van Veen, TR; Zeeman, GG, 2012) |
| "Postpartum preeclampsia/eclampsia is the presence of hypertension and proteinuria, with or without seizures, occurring up to 4 weeks after delivery." | 1.37 | Postpartum preeclampsia: emergency department presentation and management. ( Abbott, J; Bakes, K; Withers, E; Yancey, LM, 2011) |
| " This report does not suggest the routine use of low-dose spinal anesthesia without supplements, but illustrates the wide variability in dosage and sensitivity to spinal anesthetics, and suggests that further research is needed in this area, particularly in morbidly obese parturients." | 1.32 | Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications. ( Pan, PH; Reyes, M, 2004) |
| "In women with severe preeclampsia, significant increases in mean arterial pressures (MAP) are common after rapid induction of general anesthesia (GA) and tracheal intubation." | 1.30 | Changes in maternal middle cerebral artery blood flow velocity associated with general anesthesia in severe preeclampsia. ( Angel, JJ; Bush, AJ; Lawson, P; Ramanathan, J; Sibai, B, 1999) |
| "Twenty mothers with moderate to severe preeclampsia were allocated to labetalol (Trandate) or hydralazine (Apresolin) antihypertensive treatment." | 1.29 | Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment. ( Faxelius, G; Hjertberg, R; Lagercrantz, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (12.62) | 18.7374 |
| 1990's | 12 (11.65) | 18.2507 |
| 2000's | 16 (15.53) | 29.6817 |
| 2010's | 41 (39.81) | 24.3611 |
| 2020's | 21 (20.39) | 2.80 |
| Authors | Studies |
|---|---|
| Wiles, K | 1 |
| Damodaram, M | 1 |
| Frise, C | 1 |
| Bastian, IN | 1 |
| Antony, KM | 1 |
| Ohamadike, O | 1 |
| Lim, SL | 1 |
| Siegel, A | 1 |
| Zemtsov, G | 1 |
| Kuller, JA | 1 |
| Dotters-Katz, S | 1 |
| Muhammad, S | 1 |
| Usman, H | 1 |
| Dawha, YM | 1 |
| Yahya, A | 1 |
| Yekeen, A | 1 |
| Bako, B | 1 |
| Kipnis, CM | 1 |
| Daly, PL | 1 |
| Goodwin, ET | 1 |
| Smith, DK | 1 |
| Spehar, SM | 1 |
| Albert-Stone, E | 1 |
| Davis, MB | 1 |
| Mowafy, SMS | 1 |
| Medhat, MM | 1 |
| S, D | 1 |
| Novri, DA | 1 |
| Hamidy, Y | 1 |
| Savira, M | 1 |
| Cífková, R | 1 |
| Bajpai, D | 1 |
| Popa, C | 1 |
| Verma, P | 1 |
| Dumanski, S | 1 |
| Shah, S | 1 |
| Kausar, M | 1 |
| Husain, S | 1 |
| Hussain, R | 1 |
| Ashworth, D | 1 |
| Battersby, C | 1 |
| Bick, D | 1 |
| Green, M | 1 |
| Hardy, P | 1 |
| Leighton, L | 1 |
| Magee, LA | 4 |
| Maher, A | 1 |
| McManus, RJ | 2 |
| Moakes, C | 1 |
| Morris, RK | 1 |
| Nelson-Piercy, C | 4 |
| Sparkes, J | 1 |
| Rivero-Arias, O | 1 |
| Webb, A | 1 |
| Wilson, H | 1 |
| Myers, J | 2 |
| Chappell, LC | 4 |
| Peng, Z | 1 |
| Zhang, J | 1 |
| Xiao, Y | 1 |
| Dong, W | 1 |
| Webster, LM | 2 |
| Reed, K | 1 |
| Myers, JE | 2 |
| Burns, A | 1 |
| Gupta, P | 1 |
| Patel, P | 1 |
| Wiesender, C | 1 |
| Seed, PT | 2 |
| Singer, J | 3 |
| Lee, T | 3 |
| Lay-Flurrie, S | 1 |
| Rey, E | 3 |
| Logan, AG | 3 |
| von Dadelszen, P | 3 |
| Kantorowska, A | 1 |
| Heiselman, CJ | 1 |
| Halpern, TA | 1 |
| Akerman, MB | 1 |
| Elsayad, A | 1 |
| Muscat, JC | 1 |
| Sicuranza, GB | 1 |
| Vintzileos, AM | 1 |
| Heo, HJ | 1 |
| Wu, Y | 1 |
| Wang, DJ | 1 |
| Zhang, Y | 1 |
| Zhang, YX | 1 |
| Zhang, R | 1 |
| Doherty, A | 1 |
| McLaughlin, K | 1 |
| Kingdom, JC | 1 |
| Miremberg, H | 1 |
| Rubinchik-Stern, M | 1 |
| Lurie, O | 1 |
| Bar, J | 1 |
| Kovo, M | 1 |
| Woolston, E | 1 |
| Tang, Y | 1 |
| Azizi, S | 1 |
| Kando, I | 1 |
| Chamley, L | 1 |
| Stone, P | 1 |
| Chen, Q | 2 |
| Mulder, EG | 1 |
| Ghossein-Doha, C | 1 |
| Cauffman, E | 1 |
| Lopes van Balen, VA | 1 |
| Schiffer, VMMM | 1 |
| Alers, RJ | 1 |
| Oben, J | 1 |
| Smits, L | 1 |
| van Kuijk, SMJ | 1 |
| Spaanderman, MEA | 1 |
| Xiang, X | 1 |
| Wang, F | 1 |
| Zhao, N | 1 |
| Zhou, Z | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Lee, MS | 1 |
| Xiao, X | 1 |
| Xiao, F | 1 |
| Zhao, M | 1 |
| Tong, M | 1 |
| Wise, MR | 1 |
| Stone, PR | 1 |
| Chamley, LW | 1 |
| Duro-Gómez, J | 1 |
| Rodríguez-Marín, AB | 1 |
| Giménez de Azcárete, M | 1 |
| Duro-Gómez, L | 1 |
| Hernández-Angeles, C | 1 |
| Arjona-Berral, JE | 1 |
| Castelo-Branco, C | 1 |
| Amaral, LM | 1 |
| Wallace, K | 1 |
| Owens, M | 1 |
| LaMarca, B | 1 |
| Podymow, T | 1 |
| August, P | 1 |
| Dong, XY | 1 |
| Bai, CB | 1 |
| Nao, JF | 1 |
| Wang, Y | 1 |
| Shi, D | 1 |
| Chen, L | 1 |
| Mills, C | 1 |
| Watt-Coote, I | 1 |
| Khalil, A | 1 |
| Cruickshank, JK | 1 |
| Sun, CJ | 1 |
| Li, L | 1 |
| Li, XY | 1 |
| Zhang, WY | 1 |
| Liu, XW | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| Booker, WA | 1 |
| Siddiq, Z | 1 |
| Huang, Y | 1 |
| Ananth, CV | 1 |
| Wright, JD | 1 |
| Cleary, KL | 1 |
| DʼAlton, ME | 1 |
| Friedman, AM | 1 |
| O'brien, L | 1 |
| Duong, J | 1 |
| Winterton, T | 1 |
| Haring, A | 1 |
| Kuhlmann, Z | 1 |
| Gainder, S | 1 |
| Thakur, M | 1 |
| Saha, SC | 1 |
| Prakash, M | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Patel, V | 1 |
| Ramachandran, B | 1 |
| Omar, I | 1 |
| Alexander, JM | 1 |
| Wilson, KL | 1 |
| Arulkumaran, N | 1 |
| Lightstone, L | 1 |
| Xie, RH | 1 |
| Guo, Y | 1 |
| Krewski, D | 1 |
| Mattison, D | 1 |
| Nerenberg, K | 1 |
| Walker, MC | 1 |
| Wen, SW | 1 |
| Bodenmann Gobin, P | 1 |
| Gobin, N | 1 |
| Ducry, J | 1 |
| Portmann, L | 1 |
| Vial, Y | 1 |
| Vogt, B | 1 |
| Chattopadhyay, S | 1 |
| Das, A | 1 |
| Pahari, S | 1 |
| Castiella, A | 1 |
| Iglesias, U | 1 |
| Zapata, E | 1 |
| Zubiaurre, L | 1 |
| Iribarren, A | 1 |
| Gangooly, S | 1 |
| Muttukrishna, S | 1 |
| Jauniaux, E | 1 |
| Vadhera, RB | 1 |
| Simon, M | 1 |
| Thomas, B | 1 |
| Abdul Rouf, PV | 1 |
| El Kassem, W | 1 |
| Al Hail, M | 1 |
| Stewart, D | 1 |
| Tharannum, A | 1 |
| Ahmed, A | 1 |
| Al Saadi, M | 1 |
| Ross, S | 2 |
| Asztalos, E | 2 |
| Murphy, KE | 2 |
| Menzies, J | 2 |
| Sanchez, J | 2 |
| Gafni, A | 2 |
| Gruslin, A | 2 |
| Helewa, M | 2 |
| Hutton, E | 2 |
| Koren, G | 2 |
| Lee, SK | 2 |
| Ganzevoort, JW | 2 |
| Welch, R | 2 |
| Thornton, JG | 2 |
| Moutquin, JM | 2 |
| Olson-Chen, C | 1 |
| Seligman, NS | 1 |
| Kubota-Sjogren, Y | 1 |
| Sharma, KJ | 1 |
| Rodriguez, M | 1 |
| Kilpatrick, SJ | 1 |
| Greene, N | 1 |
| Aghajanian, P | 1 |
| Richter, AE | 1 |
| Schat, TE | 1 |
| Van Braeckel, KN | 1 |
| Scherjon, SA | 1 |
| Bos, AF | 1 |
| Kooi, EM | 1 |
| Shi, DD | 1 |
| Yang, FZ | 1 |
| Zhou, L | 1 |
| Wang, N | 1 |
| Barton, JR | 1 |
| Sibai, BM | 4 |
| Yancey, LM | 1 |
| Withers, E | 1 |
| Bakes, K | 1 |
| Abbott, J | 1 |
| Shafi, NA | 1 |
| Malik, A | 1 |
| Silverman, DI | 1 |
| Abdel-Hady, el-S | 1 |
| Fawzy, M | 1 |
| El-Negeri, M | 1 |
| Nezar, M | 1 |
| Ragab, A | 1 |
| Helal, AS | 1 |
| Hamaoui, A | 1 |
| Mercado, R | 1 |
| Merino, JL | 1 |
| Espejo, B | 1 |
| Ferreiro, P | 1 |
| Bueno, B | 1 |
| Paraíso, V | 1 |
| Santos Nores, J | 1 |
| Bravo López, JJ | 1 |
| Borrajo Prol, MP | 1 |
| Iglesias Forneiro, A | 1 |
| Immanni, S | 1 |
| Khan, EI | 1 |
| Staunton, M | 1 |
| Ciantar, E | 1 |
| Walker, JJ | 3 |
| Heida, KY | 1 |
| Zeeman, GG | 1 |
| Van Veen, TR | 1 |
| Hulzebos, CV | 1 |
| Liu, QQ | 1 |
| Yu, YH | 1 |
| Gong, SP | 1 |
| Huang, LP | 1 |
| Elatrous, S | 1 |
| Nouira, S | 1 |
| Ouanes Besbes, L | 1 |
| Marghli, S | 1 |
| Boussarssar, M | 1 |
| Sakkouhi, M | 1 |
| Abroug, F | 1 |
| Belfort, MA | 2 |
| Tooke-Miller, C | 1 |
| Allen, JC | 1 |
| Dizon-Townson, D | 1 |
| Varner, MA | 1 |
| Mok, CC | 1 |
| Kwan, TH | 1 |
| Chow, L | 1 |
| Reyes, M | 1 |
| Pan, PH | 1 |
| Houlihan, DD | 1 |
| Dennedy, MC | 1 |
| Ravikumar, N | 1 |
| Morrison, JJ | 1 |
| Clark, SL | 1 |
| Sibai, B | 2 |
| Frishman, WH | 1 |
| Veresh, M | 1 |
| Schlocker, SJ | 1 |
| Tejani, N | 1 |
| Omu, AE | 2 |
| Al-Harmi, J | 1 |
| Vedi, HL | 1 |
| Mlechkova, L | 1 |
| Sayed, AF | 1 |
| Al-Ragum, NS | 1 |
| Erwin, L | 1 |
| Lang, G | 1 |
| Prentice, CR | 2 |
| Belch, JJ | 1 |
| McLaren, M | 1 |
| Forbes, CD | 2 |
| Calder, AA | 3 |
| Hammerle, AF | 1 |
| Lang, GD | 1 |
| Lowe, GD | 1 |
| Lunell, NO | 1 |
| Nylund, L | 1 |
| Lewander, R | 1 |
| Sarby, B | 1 |
| Garden, A | 1 |
| Davey, DA | 1 |
| Dommisse, J | 1 |
| el-Qarmalawi, AM | 1 |
| Morsy, AH | 1 |
| al-Fadly, A | 1 |
| Obeid, A | 1 |
| Hashem, M | 1 |
| Connelly, JF | 1 |
| Hjertberg, R | 2 |
| Faxelius, G | 2 |
| Belfrage, P | 1 |
| Mahmoud, TZ | 1 |
| Bjornsson, S | 1 |
| Lagercrantz, H | 1 |
| Orpana, AK | 1 |
| Avela, K | 1 |
| Ranta, V | 1 |
| Viinikka, L | 1 |
| Ylikorkala, O | 2 |
| Makhseed, M | 1 |
| al-Qattan, F | 1 |
| Ramanathan, J | 2 |
| Angel, JJ | 1 |
| Bush, AJ | 1 |
| Lawson, P | 1 |
| Vermillion, ST | 2 |
| Scardo, JA | 2 |
| Newman, RB | 2 |
| Chauhan, SP | 2 |
| Hogg, BB | 1 |
| Varon, J | 1 |
| Marik, PE | 1 |
| Pittman, JA | 1 |
| Laml, T | 1 |
| Hartmann, BW | 1 |
| Preyer, O | 1 |
| Ruecklinger, E | 1 |
| Soeregi, G | 1 |
| Wagenbichler, P | 1 |
| Bolte, AC | 1 |
| van Geijn, HP | 1 |
| Dekker, GA | 1 |
| Hussein, M | 1 |
| Mooij, JM | 1 |
| Roujouleh, H | 1 |
| Rollins, G | 1 |
| Michael, CA | 1 |
| Olsen, KS | 2 |
| Beier-Holgersen, R | 2 |
| Haraldsson, A | 1 |
| Geven, W | 1 |
| Naden, RP | 1 |
| Redman, CW | 1 |
| Mabie, WC | 3 |
| Gonzalez, AR | 2 |
| Amon, E | 1 |
| Elkington, KW | 1 |
| Chauhan, D | 1 |
| Ruiz, AG | 1 |
| Jouppila, P | 1 |
| Kirkinen, P | 1 |
| Koivula, A | 1 |
| Moretti, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The CHIPS Trial (Control of Hypertension In Pregnancy Study)[NCT01192412] | 987 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Early Vascular Adjustments to Prevent Preeclampsia and Related Complications[NCT04216706] | 314 participants (Actual) | Observational | 2014-11-01 | Completed | |||
| Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial[NCT03262961] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-15 | Recruiting | ||
| The Effect of Prophylactic Magnesium Use in Pregnant Women on Reversal of Neuromuscular Block With Sugammadex:Evaluation With TOF[NCT05558969] | 30 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | |||
| Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET)[NCT00293735] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn (stopped due to Lack of funding) | ||
| Effectiveness of Subarachnoid Hyperbaric Bupivacaine on Mean Arterial Blood Pressure in Pregnant Patients With Obesity Operated by Cesarean Section[NCT04205344] | Phase 4 | 40 participants (Actual) | Interventional | 2017-02-01 | Completed | ||
| Effect of Subarachnoid Hyperbaric Bupivacaine on Mean Arterial Pressure in Obese Pregnant Patients Undergoing Cesarean Section[NCT06060015] | Phase 4 | 106 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278] | 0 participants (Actual) | Observational | 2008-08-31 | Withdrawn (stopped due to No participants) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pregnancy loss or NICU admission for greater than 48 hours, as recorded in the maternal and infant medical records immediately following the birth (or pregnancy loss), and then again after the mothers' and infants' discharge home. Supplemental information, about potential post-discharge maternal or neonatal morbidities in the 6 weeks following birth for the mother, or 28 days of life for the baby, will be obtained by contacting women at 6 weeks postpartum and/or from medical records. (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 155 |
| 'Tight' Control. | 150 |
"Serious maternal complications measured up to 6 weeks postpartum. Death or one or more life-threatening maternal complications:~Adverse neurological complications (stroke, eclampsia, and/or blindness), and/or~End-organ failure (uncontrolled hypertension, inotropic support, pulmonary oedema, respiratory failure, myocardial ischaemia/infarction, renal failure, coagulopathy, and/or transfusion)" (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 18 |
| 'Tight' Control. | 10 |
21 reviews available for labetalol and Pre-Eclampsia
| Article | Year |
|---|---|
Hypertensive Disorders of Pregnancy: Common Clinical Conundrums.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; P | 2022 |
Cardiac medications in obstetric patients.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Female; Hematologic Agents; Humans; Hyperte | 2023 |
Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
Evaluation and Management of Hypertensive Disorders of Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Labetalol | 2023 |
Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retarda | 2020 |
Pathophysiology and Current Clinical Management of Preeclampsia.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delivery, Obstetric; Endothelium, | 2017 |
New Evidence in the Management of Chronic Hypertension in Pregnancy.
Topics: Algorithms; Antihypertensive Agents; Blood Pressure; Chronic Disease; Female; Humans; Hypertension; | 2017 |
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Hypertensive emergencies of pregnancy.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Creatine; Diuretics; Emergency Medicine; Female; | 2013 |
Severe pre-eclampsia and hypertensive crises.
Topics: Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Critical Care; Early Dia | 2013 |
Hypertensive emergencies in pregnancy.
Topics: Antihypertensive Agents; Eclampsia; Emergencies; Female; Humans; Hydralazine; Hypertension; Hyperten | 2014 |
Hypertensive Emergencies in Pregnancy.
Topics: Antihypertensive Agents; Cesarean Section; Chronic Disease; Congenital Abnormalities; Emergencies; E | 2016 |
Pre-eclampsia, severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelets syndrome: what is new?
Topics: Anticoagulants; Antihypertensive Agents; Female; HELLP Syndrome; Heparin; Humans; Hypertension, Preg | 2011 |
[Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis].
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Infant, Newborn; | 2012 |
Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate.
Topics: Anticonvulsants; Antihypertensive Agents; Cerebrovascular Circulation; Eclampsia; Female; Humans; La | 2006 |
Pathophysiology and medical management of systemic hypertension in preeclampsia.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium; Calcium Channel Blockers; Cerebral Hemorrhage; Female | 2006 |
Antihypertensive drugs of choice for treating preeclampsia.
Topics: Antihypertensive Agents; Female; Fetal Distress; Humans; Labetalol; Nifedipine; Pre-Eclampsia; Pregn | 1994 |
The diagnosis and management of hypertensive crises.
Topics: Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Clonidine; Diazoxide; Enalaprilat; Fema | 2000 |
Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diureti | 2001 |
Antihypertensive drugs in pregnancy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diazoxide; Diuretics; Female; Fetus; Humans; H | 1985 |
26 trials available for labetalol and Pre-Eclampsia
| Article | Year |
|---|---|
Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Infant; Infant, | 2022 |
Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Female; Hemodynamics; Humans; Infusions, Intraveno | 2023 |
Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.
Topics: Antihypertensive Agents; Female; Humans; Hydralazine; Labetalol; Nifedipine; Pre-Eclampsia; Pregnanc | 2022 |
A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA).
Topics: Animals; Antihypertensive Agents; Female; Humans; Hypertension; Infant; Infant, Newborn; Labetalol; | 2023 |
Quantifying adherence to antihypertensive medication for chronic hypertension during pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Chromatography, High Pressure Liquid; | 2019 |
Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension; Hypertension, Pregnancy- | 2020 |
Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Do | 2020 |
Lipid profile and cytokines in hypertension of pregnancy: A comparison of preeclampsia therapies.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cytokines; Double-Blind Method; Drug Administration | 2018 |
Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study.
Topics: Adult; Antihypertensive Agents; Birth Weight; Black People; Blood Pressure; Chronic Disease; Cohort | 2019 |
Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy.
Topics: Adrenergic beta-Antagonists; Adult; Case-Control Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 | 2018 |
To study the changes in fetal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; F | 2019 |
Fetomaternal outcome in severe preeclamptic women undergoing emergency cesarean section under either general or spinal anesthesia.
Topics: Adolescent; Adult; Anesthesia, General; Anesthesia, Spinal; Anticonvulsants; Antihypertensive Agents | 2014 |
Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Decision-Making; Female; Humans; Hypertensi | 2016 |
Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnanc | 2016 |
Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; D | 2016 |
Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nicardipine; Pre-Eclampsia; | 2002 |
Labetalol and platelet function in pre-eclampsia.
Topics: Blood Platelets; Clinical Trials as Topic; Ethanolamines; Female; Humans; Hypertension; Labetalol; P | 1982 |
Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy.
Topics: Adult; Blood Pressure; Dihydralazine; Eclampsia; Ethanolamines; Female; Fetus; Humans; Hydralazine; | 1982 |
Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration Sched | 1995 |
Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants.
Topics: Adult; Female; Humans; Hydralazine; Infant, Low Birth Weight; Infant, Newborn; Labetalol; Pre-Eclamp | 1993 |
Effect of antihypertensive therapy in preeclampsia on levels of serum interleukin-4.
Topics: Adult; Antihypertensive Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydralazine; Infu | 1996 |
A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; | 1999 |
A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; E | 1999 |
A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; H | 1987 |
The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia.
Topics: Adolescent; Adult; Anesthesia, Obstetrical; Blood Pressure; Cesarean Section; Female; Humans; Hypert | 1988 |
A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term.
Topics: Adult; Blood Pressure; Female; Fetal Growth Retardation; Hospitalization; Humans; Labetalol; Pre-Ecl | 1987 |
56 other studies available for labetalol and Pre-Eclampsia
| Article | Year |
|---|---|
Severe hypertension in pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Pre-Eclampsia; Pre | 2021 |
Gestational weight gain among gravidae with hypertension receiving labetalol versus nifedipine.
Topics: Antihypertensive Agents; Blood Pressure; Female; Gestational Weight Gain; Humans; Hypertension; Labe | 2022 |
Hypertensive Conditions: Hypertensive Disorders in Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pre | 2022 |
Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Hypotension; Lab | 2023 |
Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia.
Topics: Antihypertensive Agents; Blood Pressure; East Asian People; Female; Humans; Hypertension; Infant, Ne | 2023 |
Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.
Topics: Administration, Intravenous; Administration, Oral; Adult; After-Hours Care; Antihypertensive Agents; | 2020 |
Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.
Topics: Administration, Oral; Adult; E-Selectin; Female; Humans; Labetalol; Magnesium Sulfate; Nifedipine; P | 2020 |
[THE EFFECT OF MAGNESIUM SULPHATE AND LABETALOL ON PLACENTAL VESSELS REACTIVITY USING THE EX-VIVO PLACENTAL PERFUSION MODEL].
Topics: Female; Fetus; Humans; Labetalol; Magnesium Sulfate; Placenta; Pre-Eclampsia; Pregnancy | 2020 |
Comparison of the effects on maternal endothelial cell activation: an in vitro study of anti-hypertensive drugs clinically used in pre-eclampsia.
Topics: Antihypertensive Agents; Endothelial Cells; Female; Humans; Labetalol; Placenta; Pre-Eclampsia; Preg | 2022 |
Preventing Recurrent Preeclampsia by Tailored Treatment of Nonphysiologic Hemodynamic Adjustments to Pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Hemodynamics; Humans; Labetalol; Methyldopa; | 2021 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Treating normal early gestation placentae with preeclamptic sera produces extracellular micro and nano vesicles that activate endothelial cells.
Topics: Cells, Cultured; Endothelial Cells; Extracellular Vesicles; Female; HMGB1 Protein; Humans; Immune Se | 2017 |
A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Administratio | 2017 |
Clinical and radiological features of posterior reversible encephalopathy syndrome in patients with pre-eclampsia and eclampsia.
Topics: Adult; Anticonvulsants; Antihypertensive Agents; Brain; Diazepam; Eclampsia; Female; Humans; Labetal | 2017 |
Use of Antihypertensive Medications and Uterotonics During Delivery Hospitalizations in Women With Asthma.
Topics: Adult; Antihypertensive Agents; Asthma; Carboprost; Contraindications, Drug; Databases, Factual; Del | 2018 |
Management of Hypertension on the Labor and Delivery Unit: Delivering Care in the Era of Protocols and Algorithms.
Topics: Algorithms; Antihypertensive Agents; Delivery Rooms; Delivery, Obstetric; Female; Guideline Adherenc | 2018 |
Posterior reversible encephalopathy syndrome, preeclampsia or stroke? A diagnostic dilemma.
Topics: Abdominal Pain; Adrenergic beta-Antagonists; Aspirin; Diagnosis, Differential; Factor V; Female; Hea | 2019 |
Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Hypertens | 2013 |
[Electrolyte disorders in preeclampsia. A case report].
Topics: Adult; Aldosterone; Antihypertensive Agents; Capillary Leak Syndrome; Cesarean Section; Emergencies; | 2014 |
[Toxic hepatocellular hepatitis due to labetalol].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Asymptomatic Diseases; Chemical and Drug Induced Liv | 2015 |
In-vitro study of the effect of anti-hypertensive drugs on placental hormones and angiogenic proteins synthesis in pre-eclampsia.
Topics: Activins; Angiogenic Proteins; Antigens, CD; Antihypertensive Agents; Chorionic Gonadotropin; Chorio | 2014 |
A case of probable labetalol induced hyperkalaemia in pre-eclampsia.
Topics: Antihypertensive Agents; Female; Humans; Hyperkalemia; Labetalol; Pre-Eclampsia; Pregnancy; Young Ad | 2014 |
Fulminant antenatal pulmonary oedema in a woman with hypertension and superimposed preeclampsia.
Topics: Adult; Antihypertensive Agents; Cesarean Section; Female; Follow-Up Studies; Humans; Hypertension; L | 2015 |
Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension, Pregnancy | 2016 |
The Effect of Maternal Antihypertensive Drugs on the Cerebral, Renal and Splanchnic Tissue Oxygen Extraction of Preterm Neonates.
Topics: Antihypertensive Agents; Brain; Cerebrovascular Circulation; Female; Gestational Age; Hemodynamics; | 2016 |
Controversies Regarding Diagnosis and Treatment of Severe Hypertension in Pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Labetalol; Pre-E | 2017 |
Postpartum preeclampsia: emergency department presentation and management.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Antihypertensive Agents; Benzodiazepines; E | 2011 |
Management of Takayasu arteritis during pregnancy.
Topics: Adult; Angiography; Antihypertensive Agents; Cesarean Section; Diagnosis, Differential; Female; Gluc | 2009 |
Is expectant management of early-onset severe preeclampsia worthwhile in low-resource settings?
Topics: Adolescent; Adult; Antihypertensive Agents; Egypt; Female; Fetal Death; Fetal Monitoring; Gestationa | 2010 |
Association of preeclampsia and myasthenia: a case report.
Topics: Antihypertensive Agents; Cesarean Section; Cholinesterase Inhibitors; Female; HELLP Syndrome; Humans | 2009 |
[Pregnancy and advanced chronic kidney disease].
Topics: Ductus Arteriosus, Patent; Epilepsy; Female; Fetal Growth Retardation; Humans; Hyaline Membrane Dise | 2010 |
[HTA-pre-eclampsia-postpartum haemolytic-uraemic syndrome: good results can be achieved].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antihypertensive Agents; C | 2010 |
Hypoglycaemia secondary to labetalol infusion.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypoglycemia; Infusions, Intravenous; Labetalol; Pre | 2011 |
Neonatal side effects of maternal labetalol treatment in severe preeclampsia.
Topics: Adult; Antihypertensive Agents; Case-Control Studies; Female; Fetal Death; Humans; Infant Mortality; | 2012 |
Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2002 |
Scleroderma renal crisis sine scleroderma during pregnancy.
Topics: Adult; Antihypertensive Agents; Arteries; Captopril; Drug Therapy, Combination; Female; Humans; Hype | 2003 |
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; | 2004 |
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; | 2004 |
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; | 2004 |
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; | 2004 |
Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance.
Topics: Adult; Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Fetus; Humans; Hydralazine | 2004 |
Magnesium sulphate therapy in women with pre-eclampsia and eclampsia in Kuwait.
Topics: Adult; Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Eclampsia; Fema | 2008 |
[New aspects in the therapy of pregnancy-induced hypertension].
Topics: Anesthesia, Epidural; Epoprostenol; Female; Fenoterol; Humans; Hypertension; Labetalol; Metoprolol; | 1983 |
Blood rheology in pre-eclampsia and intrauterine growth retardation: effects of blood pressure reduction with labetalol.
Topics: Adult; Bed Rest; Blood Pressure; Blood Viscosity; Ethanolamines; Female; Fetal Growth Retardation; H | 1984 |
Acute effect of an antihypertensive drug, labetalol, on uteroplacental blood flow.
Topics: Blood Pressure; Depression, Chemical; Ethanolamines; Female; Heart Rate; Humans; Indium; Labetalol; | 1982 |
Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome.
Topics: Adult; Female; Fetus; Humans; Labetalol; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy Complications | 1993 |
Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment.
Topics: Adolescent; Adult; Female; Fetal Hypoxia; Hemodynamics; Humans; Hydralazine; Infant, Newborn; Labeta | 1993 |
The calcium-dependent nitric oxide production of human vascular endothelial cells in preeclampsia.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Calcimycin; Calcium; Cell Count; Cells, Cultur | 1996 |
Changes in maternal middle cerebral artery blood flow velocity associated with general anesthesia in severe preeclampsia.
Topics: Adult; Anesthesia, General; Anesthetics, Intravenous; Antihypertensive Agents; Blood Flow Velocity; | 1999 |
Magnesium sulphate for pre-eclampsia and a sudden bradycardia.
Topics: Adolescent; Adrenergic beta-Antagonists; Bradycardia; Calcium Channel Blockers; Drug Interactions; F | 2000 |
Serum leptin concentration in cord blood: relationship to birth weight and gender in pregnancies complicated by pre-eclampsia.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Fetal Blood; Gestational Age; Humans; Hyperten | 2000 |
Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension.
Topics: Antihypertensive Agents; Apgar Score; Cesarean Section; Comorbidity; Disease Susceptibility; Female; | 2001 |
Guidelines on high blood pressure in pregnancy give new classifications of disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Contra | 2000 |
The treatment of hypertension in pregnancy.
Topics: Adolescent; Adult; Anticonvulsants; Antihypertensive Agents; Bethanidine; Eclampsia; Female; Humans; | 1978 |
Fetal death following labetalol administration in pre-eclampsia.
Topics: Adult; Cesarean Section; Female; Fetal Death; Humans; Labetalol; Pre-Eclampsia; Pregnancy; Premedica | 1992 |
Hemodynamic collapse following labetalol administration in preeclampsia.
Topics: Adult; Cesarean Section; Female; Humans; Hypotension; Labetalol; Pre-Eclampsia; Pregnancy; Premedica | 1992 |
Severe adverse effects of maternal labetalol in a premature infant.
Topics: Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Labetalol; Maternal-Fetal Exchange; Pr | 1989 |
A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term.
Topics: Female; Hospitalization; Humans; Labetalol; Pre-Eclampsia; Pregnancy | 1988 |
Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in pre-eclampsia.
Topics: Blood Pressure; Epoprostenol; Female; Fetus; Heart Rate; Hemodynamics; Humans; Labetalol; Placenta; | 1986 |